Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

21.50 +0.34 (+1.61%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Genmab A/S ADR

< Previous 1 2 3 4 5 6 7 8 Next >
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
GENMAB A/S -SP ADR (NASDAQ:GMAB) is showing decent growth, but is still valued reasonably. 
Via Chartmill
NASDAQ:GMAB, an undervalued stock with good fundamentals.
GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
Exposures Product Safety
10 Analysts Assess Genmab: What You Need To Know
Via Benzinga
What 9 Analyst Ratings Have To Say About Genmab
Via Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Investors seeking growth at a reasonable cost should explore GENMAB A/S -SP ADR (NASDAQ:GMAB). 
Via Chartmill
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
7 Stocks That Could Safely 10X by 2030
Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align. 
Via InvestorPlace
Decoding 9 Analyst Evaluations For Genmab
Via Benzinga
NASDAQ:GMAB is not too expensive for the growth it is showing.
Via Chartmill
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
Exploring the Growth Potential of GENMAB A/S -SP ADR (NASDAQ:GMAB) as It Nears a Breakout. 
Via Chartmill
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
From Genmab A/S
Via Business Wire
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
From Genmab A/S
Via Business Wire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
From Genmab A/S
Via Business Wire
GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024
GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate. 
Via Investor's Business Daily
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a... 
Via Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
Genmab is buying a privately held company focused on antibody drug conjugates. 
Via Investor's Business Daily
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.